Related Experiment Videos
Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
Nathamon Panomuppakarn1, Patamintita Witoonpanich2, Jariya Waisayarat3
1Division of Medical Oncology Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand.
Clinical Case Reports
|October 14, 2017
Abstract:
Systemic treatment of Medullary thyroid carcinoma (MTC) is currently limited to the use of a tyrosine kinase inhibitor. Cytotoxic chemotherapy is not routinely recommended in the earlier lines of treatment due to the lack of efficacy. We describe a patient with locally advanced MTC who had an uncommon response to cisplatin and etoposide.